VYNE Therapeutics
Therapies for the Treatment of Immuno-inflammatory Conditions
Company Overview
Snapshot
Founded in January 2003 by Meir Eini, VYNE Therapeutics operates with 51–200 employees. The company has raised $180M across four funding rounds from two investors. In November 2022, VYNE Therapeutics announced the first subjects dosed in a Phase 1a/b clinical trial evaluating its Pan-BET Inhibitor, VYN201, for the treatment of Vitiligo.
Business overview
VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for immuno-inflammatory conditions. The company leverages its Molecule Stabilizing Technology to develop and commercialize solutions, including FDA-approved AMZEEQ (minocycline) topical foam, 4%, for topical minocycline, and ZILXI (minocycline) topical foam, 1.5%, for rosacea treatment. VYNE Therapeutics serves the dermatology and broader pharmaceutical markets, operating within the Health Tech & Life Sciences sector.
Strategic signal
In January 2023, VYNE Therapeutics announced that the first vitiligo patient was dosed in the Phase 1a/b clinical trial for its novel BET Inhibitor VYN201. This advancement signals the company's continued commitment to developing innovative treatments for immuno-inflammatory conditions and expands its pipeline beyond its existing FDA-approved topical foam products, indicating potential for future growth in new therapeutic areas.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent clinical development for VYNE Therapeutics?
- In January 2023, VYNE Therapeutics announced the first vitiligo patient was dosed in the Phase 1a/b clinical trial for its novel BET Inhibitor VYN201.
- When did VYNE Therapeutics announce the availability of ZILXI in pharmacies?
- In October 2020, VYNE Therapeutics announced that ZILXI (minocycline) topical foam, 1.5% became available in pharmacies nationwide.
- What was a key corporate change for the company in 2020?
- In September 2020, Menlo Therapeutics completed its corporate name change to VYNE Therapeutics, following its merger with Foamix Pharmaceuticals.
- Which investors participated in the July 2019 funding round?
- In July 2019, the company raised funding from investors including Perceptive Advisors and OrbiMed.
- What was a notable regulatory milestone for Foamix Pharmaceuticals before the merger?
- In March 2019, Foamix announced FDA acceptance of its New Drug Application for FMX101 Minocycline Foam for the treatment of moderate to severe acne.